W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę cookies.

Powrót

JOINT ACTIONS and DIRECT GRANTS TO MEMBER STATES’ AUTHORITIES (OTHER THAN JOINT ACTIONS)

Program Pracy na 2023 r.

  • EU4H-2023-JA-01: Direct grant to Member States’ authorities: global health impact (HS-g-23-71-01) - EUR 4 700 000 EU co-funding – NFZ (CA)
  • EU4H-2023-JA-02: Direct Grant to Member States authorities: to enhance, extend and consolidate wastewater surveillance for public health (HERA) (CP-g-23-18)
    - EUR 15 000 000 EU co-funding – bez zgłoszenia
  • EU4H-2023-JA-03: Direct grants to Member States’ authorities: ‘Healthier Together’ EU NCD initiative – Chronic respiratory diseases (CRDs) (DP-g-23-31-01)
    - EUR 4 000 000 EU co-funding – NFZ (CA) i WUM (AE)
  • EU4H-2023-JA-04: Direct grants to Member States’ authorities: ‘Healthier Together’ EU NCD initiative – Mental health (DP-g-23-32-01) - EUR 6 000 000 EU co-funding
    – NFZ (CA), IPiN i WUM (AE)
  • EU4H-2023-JA-05: Direct grants to Member States’ authorities: ‘Healthier Together’ EU NCD initiative – Dementia and other neurological disorders (DP-g-23-33-01)
    - EUR 4 000 000 EU co-funding – WUM (CA), IBB PAN (AE)
  • EU4H-2023-JA-06: Direct grants to Member States’ authorities: Implementation of cancer screening programmes (CR-g-23-38) - EUR 31 000 000 EU co-funding
    – NIO-PIB (CA) i IGiChP (AE)
  • EU4H-2023-JA-07: Direct grants to Member States’ authorities: to establish an EU network of Comprehensive Cancer Infrastructures (CR-g-23-40.1)
    - EUR 90 000 000 EU co-funding – NIZP-PZH (CA) i NIO-PIB, GUMed, DCOPiH, UEW, UMLUB, IGiChP (AE)
  • EU4H-2023-JA-08: Direct grants to Member States’ authorities: to establish new networks of expertise on cancers and cancer conditions (CR-g-23-40.2)
    - EUR 40 500 000 EU co-funding – NIO-PIB (CA) i NIZH-PZH, IGiChP, WUM, UMLUB, IBB PAN (AE)
  • EU4H-2023-JA-09: Direct grants to Member States’ authorities: to support implementation of the strategic agenda for medical ionising radiation applications (SAMIRA) – Preparatory activities  for a future joint action on quality and safety of medical applications of ionising radiation under the SAMIRA initiative (CR-g-23-44-03)
    - EUR 1 000 000 EU co-funding – NIO-PIB o. Gliwice
  • EU4H-2023-JA-10: Direct grants to Member States’ authorities: preparatory activities for the reuse of data in the proposed European Health Data Space (DI-g-23-79)
    - EUR 4 000 000 EU co-funding – DI w MZ (CA), CeZ, AMB i NFZ (AE)

 

Dotacje bezpośrednie dla organów państw członkowskich (inne niż wspólne działania)

  • EU4H-2023-DGA-MS-IBA-01: Direct grants to Member States’ authorities: improving and strengthening national surveillance systems (Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU) (CP-g-23-01) - EUR 97 300 000 EU co-funding
    – GIS (CA) i NIZP-PZH (AE)
  • EU4H-2023-DGA-MS-IBA-04: Direct grants to Member States’ authorities: increase health data semantic interoperability and build national capacity on health terminologies (DI-g-23-75)
    - EUR 5 400 000 EU co-funding – NFZ (CA) i WUM (AE)
  • EU4H-2023-DGA-MS-IBA-05: Direct grants to Member States’ authorities: development and enhancement of MyHealth@EU services, including vaccination card services (DI-g-23-77)
    - EUR 4 000 000 EU co-funding – NFZ (CA)

 

W przypadku dwóch poniższych dotacji bezpośrednich:

  • EU4H-2023-DGA-MS-IBA-02: Direct grants to nominated EU reference laboratories (II): support the set-up and operation of the EU reference laboratories for the Diagnostics of Human Pathogens Network (Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU) (WP2023 reference: CP-g-23-05-01)
  • EU4H-2023-DGA-MS-IBA-03: Direct grant to EU reference laboratories for the Union contribution on in vitro diagnostic medical devices (WP2023 reference: HS-g-23-62);

beneficjenci są nominowani w drodze specjalnej procedury wyboru przeprowadzonej przez KE.
 

Program Pracy na 2022 r.

  • EU4H-2022-JA-01: Direct grants to Member States’ authorities: implementation of AMR measures in Member States (AWP1 Ref: CP-g-22-02.01)
    – EUR 50 000 000 EU co-funding – NIL (CA) oraz NIZP PZH-PIB, UMLUB i SGGW (AE)
  • EU4H-2022-JA-02: Direct grants to Member States’ authorities: Cancer and other NCDs prevention – action on health determinants (AWP Ref: CR-g-22-08.01)
    – EUR 75 000 000 EU co-funding – ŚUM (CA) oraz Miasto Rybnik i Miasto Zabrze (AE)
  • EU4H-2022-JA-03: Direct grants to Member States’ authorities: prevention of NCDs – cardiovascular diseases and diabetes (AWP Ref: DP-g-22-06.03)
    – EUR 55 000 000 EU co-funding - UMP (CA) oraz ŚUM (AE)
  • EU4H-2022-JA-04: Direct grant to Member States’ authorities: contribution to the Cancer Inequalities Registry to monitor national cancer control policies (AWP Ref: CR-g-22-10.03)
    – EUR 1 000 000 EU co-funding – DL w MZ
  • EU4H-2022-JA-05: Direct grants to Member States’ authorities: support ERNs integration to the national healthcare systems of Member States (AWP Ref: HS-g-22-16.02)
    – EUR 11 200 000 EU co-funding - DL w MZ
  • EU4H-2022-JA-06: Direct grants to Member States’ authorities: increasing capacity building of the EU medicines regulatory network (AWP Ref: HS-g-22-17.02)
    – EUR 8 000 000 EU co-funding – UMLUB (CA)
  • EU4H-2022-JA-07: Direct grants to Member States’ authorities: piloting a new model approach for assessing and authorising novel Blood, Tissues and Cells (BTC) preparation processes (AWP Ref: HS-g-22-18.01)
    – EUR 1 500 000 EU co-funding - UMP (CA)
  • EU4H-2022-JA-08: Direct grants to Member States’ authorities: reinforced market surveillance of medical devices and in vitro medical devices (AWP Ref: HS-g-22-19.01)
    – EUR 4 000 000 EU co-funding – URPL (CA)
  • EU4H-2022-JA-09: Direct grants to Member States’ authorities: preparatory actions for a European Health Data Space; primary use of data (for healthcare) and reuse of data (AWP Ref: DI-g-22-22.06)
    – EUR 4 000 000 EU co-funding – CeZ (CA)

 

Dotacje bezpośrednie dla organów państw członkowskich (inne niż wspólne działania)

  • EU4H-2022-DGA-MS-IBA-01: Direct grants to Member States’ authorities: enhancing whole genome sequencing (WGS) and/or reverse transcription polymerase chain reaction (RT-PCR) national infrastructures and capacities to respond to the COVID-19 pandemic and future health threats (HERA) (AWP Ref: CP-g-22-01.04)
    – EUR 39 000 000 EU co-funding.

Sub-topic 2: Consolidation of WGS and RT-PCR activities in countries that received support in 2021 aiming to ensure the sustainable use and integration of enhanced infrastructure into routine surveillance and outbreak investigation activities, in synergy with relevant on-going work at international level – NIZP PZH-PIB (CA)

  • EU4H-2022-DGA-MS-IBA-02: Direct grants to Member States’ authorities: supporting the maintenance of the European Medical Device Nomenclature (AWP Ref: HS-g-22-19.02)
    – EUR 1 800 000 EU co-funding. It is essential that the Italian Health Ministry continues to provide its support and competences, ensuring adequate maintenance of the EMDN – URPL (CA)
  • EU4H-2022-DGA-MS-IBA-03: Direct grants to Member States’ authorities: expansion of MyHealth@EU Digital Service Infrastructure (eHDSI) with new services and to more Member States (AWP Ref: DI-g-22-21.01)
    – EUR 30 000 000 EU co-funding – CeZ (CA)
  • EU4H-2022-DGA-MS-IBA-04: Direct grants to Member States’ authorities: setting up services by Health Data Access Bodies – Secondary use of health data (AWP Ref: DI-g-22-22.01)
    – EUR 30 000 000 EU co-funding – CeZ (CA)
  • EU4H-2022-DGA-MS-IBA-05: Direct grants to Member States’ authorities: setting up a coordinated surveillance system under the One Health approach for cross-border pathogens that threaten the Union (AWP Ref: CP-g-22-04.01)
    – EUR 20 000 000 EU co-funding – PIWet-PIB Puławy (CA)

 

Program Pracy na 2021 r.

  • EU4H-2021-JA-01: Support to coordinated and expedited assessment of clinical trials for COVID-19 therapeutics – URPL (CA)
  • EU4H-2021-JA-02: Support to assist Member States to roll out large-scale human papillomavirus vaccination campaigns -  NIZP-PIB (CA)
  • EU4H-2021-JA-03: Network of Comprehensive Cancer Centres: Preparatory activities on creation of National Comprehensive Cancer Centres and EU Networking - NIZP-PZH (CA)
  • EU4H-2021-JA-04: Network of Comprehensive Cancer Centres: Establishment of new EU Network of Expertise on Cancers and Cancer Conditions -  NIO-PIB (CA)
  • EU4H-2021-JA-05: Strengthening eHealth, integrating telemedicine and remote monitoring in health and care systems for cancer prevention and care - NIO-PIB (CA)
  • EU4H-2021-JA-06: Availability of medicines, shortages and security of supply – bez zgłoszenia
  • EU4H-2021-JA-07: Union and national surveillance systems – NIZP-PZH (CA)
  • EU4H-2021-JA-08.1: Implementation of best practices and research results on prevention of non-communicable diseases and risk factors Thematic area Diabetes: Reverse Diabetes2 Now  - NFZ (CA)
  • EU4H-2021-JA-08.2: Implementation of best practices and research results on prevention of non-communicable diseases and risk factors
    Thematic area: Healthy Lifestyle:- Smart Family oraz Grünau moves. Community-based health promotion and obesity prevention for children living in a deprived district - NFZ (CA)
  • EU4H-2021-JA-09: Transfer of best practices in primary care – NFZ (CA)
  • EU4H-2021-JA-10: Health workforce to meet health challenges – forecasting and planning for workforce in the healthcare sector  - MZ DAS (CA)
  • EU4H-2021-JA-11: To promote quality of medicines and to increase cooperation between the Member States and between the Union and third countries through trainings, joint audits, reassessments and inspections on good manufacturing and good distribution practices (GDP). Implementation of international mutual recognition agreements on pharmaceutical 2 good manufacturing practices (GMP) with the United States, Switzerland, Australia, Japan, New Zealand, Canada, Israel, the UK, and cooperation with third countries such as China and India – GIF (CA)
  • EU4H-2021-JA-12: Safety assessment cooperation and facilitated conduct of clinical trials – URPL (CA)
{"register":{"columns":[]}}